Pear Therapeutics is a company.
Pear Therapeutics has raised $80.0M across 1 funding round.
Key people at Pear Therapeutics.
Pear Therapeutics has raised $80.0M in total across 1 funding round.
Key people at Pear Therapeutics.
Pear Therapeutics has raised $80.0M in total across 1 funding round.
Pear Therapeutics's investors include f7 Ventures, General Catalyst.
# Pear Therapeutics: High-Level Overview
Pear Therapeutics is a leader in prescription digital therapeutics (PDTs), a new class of clinically validated, software-based medicines designed to treat serious diseases.[1] Founded in 2013 and headquartered in Boston, Massachusetts, the company has pioneered an end-to-end platform for discovering, developing, and delivering PDTs that work alone or in combination with pharmaceuticals.[1][2]
The company serves patients, clinicians, and payers by offering software-based treatment alternatives that improve patient outcomes, provide clinicians with better engagement and tracking tools, and deliver cost-effective solutions for healthcare systems.[1] Pear addresses large market opportunities: its three FDA-authorized products target over 20 million patients with substance and opioid use disorders and over 30 million with chronic insomnia in the U.S. alone.[1]
# Origin Story
Pear Therapeutics was founded in 2013 with a mission to transform healthcare through prescription digital therapeutics.[2] The company emerged during a convergence of healthcare trends: chronic disease driving spending, provider shortages limiting access to care, the shift toward telemedicine accelerated by COVID-19, and ubiquitous mobile device adoption.[6] This timing positioned Pear to pioneer a new therapeutic modality—software-based treatments that could address treatment access barriers including stigma, logistical hurdles, and pharmacological limitations.[6]
The company achieved early traction by becoming the first to obtain FDA marketing authorization for a PDT. Its lead product, reSET® for substance use disorder, was the first PDT to receive FDA clearance to treat disease.[1][2] This was followed by reSET-O® for opioid use disorder (the first PDT to receive Breakthrough Designation) and Somryst® for chronic insomnia (the first PDT submitted through FDA's traditional 510(k) pathway).[1][2] In June 2021, Pear went public on Nasdaq under the ticker PEAR, expanding its platform for third-party product distribution opportunities.[1][2]
# Core Differentiators
# Role in the Broader Tech Landscape
Pear sits at the intersection of healthcare disruption and digital transformation. The company is riding several converging trends: the shift from reactive to preventive care, the growing acceptance of digital health solutions post-COVID, provider shortages in behavioral health and chronic disease management, and payer demand for cost-effective alternatives to traditional pharmaceuticals and in-person therapy.[6]
The timing is critical because healthcare systems are under pressure to improve outcomes while controlling costs, and PDTs offer a scalable, less invasive treatment modality with fewer side effects and better adherence potential than traditional approaches.[6] Pear's regulatory achievements—particularly FDA's recognition of PDTs as a legitimate therapeutic class—have legitimized software as medicine and opened pathways for competitors, effectively reshaping how the healthcare industry views digital health.
# Quick Take & Future Outlook
Pear Therapeutics has successfully established prescription digital therapeutics as a new frontier in medicine, moving beyond wellness apps into clinically validated, FDA-regulated treatments. The company's public status and expanding pipeline position it to capture significant market share in behavioral health and chronic disease management as healthcare systems increasingly adopt digital-first care models.
The next phase will likely involve scaling third-party distribution of its platform, expanding its pipeline toward FDA clearance, and demonstrating long-term health economic value to payers—the ultimate gatekeepers of adoption. As provider shortages persist and digital health expectations continue rising, Pear's ability to deliver measurable clinical outcomes through software will determine whether PDTs become standard-of-care across multiple therapeutic areas or remain a niche innovation.
Pear Therapeutics has raised $80.0M across 1 funding round. Most recently, it raised $80.0M Series D in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2020 | $80.0M Series D | f7 Ventures, General Catalyst |
